Literature DB >> 23140299

Androgen receptor in human health: a potential therapeutic target.

Hifzur Rahman Siddique1, Sanjeev Nanda, Aijaz Parray, Mohammad Saleem.   

Abstract

Androgen is a key for the activation of Androgen Receptor (AR) in most of the disease conditions, however androgen-independent activation of AR is also found in aggressive type human malignancies. An intense search for the inhibitors of AR is underway to cure AR-dependent diseases. In addition to targeting various components of AR signaling pathway, compounds which directly target AR are under preclinical and clinical investigation. Various In vitro and preclinical animal studies suggest that different natural compounds have potential to act against AR. Some natural compounds have been found to be pharmacologically effective against AR irrespective of varying routs of administration viz; oral, intra-peritoneal and intravenous. This mini-review summarizes the studies conducted with different natural agents in determining their pharmacological utility against AR signaling.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23140299     DOI: 10.2174/138945012804545579

Source DB:  PubMed          Journal:  Curr Drug Targets        ISSN: 1389-4501            Impact factor:   3.465


  4 in total

1.  Identification of androgen receptor splice variant transcripts in breast cancer cell lines and human tissues.

Authors:  Dong Gui Hu; Theresa E Hickey; Connie Irvine; Dhilushi Dodampege Wijayakumara; Lu Lu; Wayne D Tilley; Luke A Selth; Peter I Mackenzie
Journal:  Horm Cancer       Date:  2014-02-26       Impact factor: 3.869

2.  Integration of VDR genome wide binding and GWAS genetic variation data reveals co-occurrence of VDR and NF-κB binding that is linked to immune phenotypes.

Authors:  Prashant K Singh; Patrick R van den Berg; Mark D Long; Angie Vreugdenhil; Laurie Grieshober; Heather M Ochs-Balcom; Jianmin Wang; Sylvie Delcambre; Sami Heikkinen; Carsten Carlberg; Moray J Campbell; Lara E Sucheston-Campbell
Journal:  BMC Genomics       Date:  2017-02-06       Impact factor: 3.969

3.  Activation of p53 and destabilization of androgen receptor by combinatorial inhibition of MDM2 and MDMX in prostate cancer cells.

Authors:  Harman Chopra; Zara Khan; Jamie Contreras; Herui Wang; Abanob Sedrak; Yan Zhu
Journal:  Oncotarget       Date:  2017-12-15

4.  BMI1 polycomb group protein acts as a master switch for growth and death of tumor cells: regulates TCF4-transcriptional factor-induced BCL2 signaling.

Authors:  Hifzur Rahman Siddique; Aijaz Parray; Rohinton S Tarapore; Lei Wang; Hasan Mukhtar; R Jeffery Karnes; Yibin Deng; Badrinath R Konety; Mohammad Saleem
Journal:  PLoS One       Date:  2013-05-06       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.